OR WAIT null SECS
September 11, 2023
The agreement states that Orbit will implement its bead-based peptide display engine to discover peptide leads specific to targets related to specific tumors.
September 08, 2023
The new policy will require trading partners to supply, accept, and manage all documentation of product and ownership of prescription drugs electronically.
September 07, 2023
Illumina’s new solutions center in Bengaluru, India, will expand access to genomics in the country.
Optibrium announced on Aug. 31, 2023 the acquisition of BioPharmics to further expand the 3D drug design and modelling offering and to focus on research and development and application science.
September 06, 2023
Further expansions of the pharmaceutical development and manufacturing services of ten23 are happening at the BASE and VIVA facilities to continue to support complex sterile product development, testing, and manufacturing.
September 05, 2023
Novo Nordisk receives the full rights to develop and commercialize the lead program.
Both companies have a focus to developing and commercializing treatments for rare diseases with a strong focus on patients and supporting communities with little to no existing therapeutic options.
September 03, 2023
Tumour-infiltrating lymphocyte (TIL) therapies offer a new route to target cancer.
September 02, 2023
European vaccine manufacturing is being boosted with high level investments.
There are many promising trials in the pipeline that may bring big news for major therapeutic areas.